# Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Chronic Hepatitis C Virus Infection Without Cirrhosis

> **NCT02114177** · PHASE3 · COMPLETED · sponsor: **Janssen Infectious Diseases BVBA** · enrollment: 310 (actual)

## Conditions studied

- Hepatitis C Virus Infection

## Interventions

- **DRUG:** Simeprevir
- **DRUG:** Simeprevir
- **DRUG:** Sofosbuvir
- **DRUG:** Sofosbuvir

## Key facts

- **NCT ID:** NCT02114177
- **Lead sponsor:** Janssen Infectious Diseases BVBA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04
- **Primary completion:** 2015-01
- **Final completion:** 2015-04
- **Target enrollment:** 310 (ACTUAL)
- **Last updated:** 2016-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02114177

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02114177, "Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Chronic Hepatitis C Virus Infection Without Cirrhosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02114177. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*